Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

36.36USD
15 Jun 2018
Change (% chg)

$0.20 (+0.55%)
Prev Close
$36.16
Open
$36.22
Day's High
$36.39
Day's Low
$36.04
Volume
25,836,778
Avg. Vol
7,673,430
52-wk High
$39.43
52-wk Low
$32.33

Select another date:

Thu, Jun 7 2018

Photo

Pfizer wins appeal against UK fine for epilepsy drug price hike

LONDON Pfizer Inc and Flynn Pharma won an appeal on Thursday against fines totalling nearly 90 million pounds ($120 million) imposed in 2016 for ramping up the cost of an epilepsy drug.

Pfizer wins appeal against UK fine for epilepsy drug price hike

LONDON, June 7 Pfizer Inc and Flynn Pharma won an appeal on Thursday against fines totalling nearly 90 million pounds ($120 million) imposed in 2016 for ramping up the cost of an epilepsy drug.

Pfizer pumps $600 million into venture capital arm

Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

Pfizer pumps $600 million into venture capital arm

Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

Pfizer pumps $600 mln into venture capital arm

June 6 Pfizer Inc said on Wednesday it planned to invest $600 million in its venture capital fund, a quarter of which would be earmarked for promising research on neuroscience.

FDA clears Pfizer's Xeljanz for inflammatory bowel disease

The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

UPDATE 1-FDA clears Pfizer's Xeljanz for inflammatory bowel disease

May 30 The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc's drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

FDA approves Pfizer's Xeljanz to treat ulcerative colitis

May 30 The U.S. Food and Drug Administration on Wednesday approved Pfizer Inc's drug Xeljanz to treat adults with moderately to severely active ulcerative colitis, making it the first oral drug to be approved for chronic use in such patients.

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

Australian anti-trust watchdog loses appeal against Pfizer over Lipitor sales

MELBOURNE An Australian court dismissed an appeal by the nation's anti-trust watchdog in a case against Pfizer Inc in which the regulator alleged the company had used its market power to limit competition for its cholesterol-lowering drug Lipitor.

Select another date: